{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:32:01Z","timestamp":1787761921554,"version":"build-2784847793"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":68,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejphar.2022.175440","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T13:24:55Z","timestamp":1669901095000},"page":"175440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development of a novel Poly (I:C)-induced murine model with accelerated lupus nephritis and examination of the therapeutic effects of mycophenolate mofetil and a cathepsin S inhibitor"],"prefix":"10.1016","volume":"938","author":[{"given":"Yuka","family":"Kawato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiko","family":"Fukahori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hiramitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuaki","family":"Morokata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175440_bib1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/ki.1990.14","article-title":"Lupus nephritis: correlation of interstitial cells with glomerular function","volume":"37","author":"Alexopoulos","year":"1990","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2022.175440_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejphar.2022.175440_bib3","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175440_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100042","article-title":"Urinary biomarkers in lupus nephritis","volume":"3","author":"Aragon","year":"2020","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.ejphar.2022.175440_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nm1590","article-title":"TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity","volume":"13","author":"Baccala","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2022.175440_bib6","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2022.175440_bib7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.175440_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11113199","article-title":"Serum and urine interferon gamma-induced protein 10 (IP-10) levels in lupus nephritis","volume":"11","author":"Brady","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejphar.2022.175440_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12026-012-8270-1","article-title":"TLR7 and TLR9 in SLE: when sensing self goes wrong","volume":"53","author":"Celhar","year":"2012","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ejphar.2022.175440_bib10","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.immuni.2006.07.013","article-title":"Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus","volume":"25","author":"Christensen","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2022.175440_bib11","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/rheumatology\/ker101","article-title":"Assessment of a lupus nephritis cohort over a 30-year period","volume":"50","author":"Croca","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2022.175440_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.676082","article-title":"IFN-I mediates lupus nephritis from the beginning to renal fibrosis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2022.175440_bib13","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/S0140-6736(19)30237-5","article-title":"Management strategies and future directions for systemic lupus erythematosus in adults","volume":"393","author":"Durcan","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2022.175440_bib14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.ejphar.2022.175440_bib15","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1007\/s10067-017-3811-6","article-title":"Pristane-induced lupus: considerations on this experimental model","volume":"36","author":"Freitas","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.175440_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.immuni.2011.05.010","article-title":"Unc93B1 restricts systemic lethal inflammation by orchestrating Toll-like receptor 7 and 9 trafficking","volume":"35","author":"Fukui","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2022.175440_bib17","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6194864","article-title":"Role of chemokine (C-X-C motif) ligand 10 (CXCL10) in renal diseases","volume":"2020","author":"Gao","year":"2020","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejphar.2022.175440_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100291","article-title":"Adults with systemic lupus exhibit distinct molecular phenotypes in a cross-sectional study","volume":"20","author":"Guthridge","year":"2020","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejphar.2022.175440_bib19","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.ejphar.2022.175440_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1523-1755.2001.00492.x","article-title":"Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages","volume":"59","author":"Hill","year":"2001","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2022.175440_bib21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1084\/jem.20081761","article-title":"Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3","volume":"206","author":"Iwakiri","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2022.175440_bib22","article-title":"High systemic type I interferon activity is associated with active class III\/IV lupus nephritis","author":"Iwamoto","year":"2021","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.175440_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/sj.gene.6364329","article-title":"Genetic susceptibility to polyI:C-induced IFNalpha\/beta-dependent accelerated disease in lupus-prone mice","volume":"7","author":"Jorgensen","year":"2006","journal-title":"Gene Immun."},{"key":"10.1016\/j.ejphar.2022.175440_bib24","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s10157-018-1597-8","article-title":"The first year results of mizoribine\/tacrolimus-based multitarget treatment for consecutive patients with lupus nephritis","volume":"22","author":"Kagawa","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175440_bib25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000486933","article-title":"Recent advances in treatment strategies for lupus nephritis","volume":"195","author":"Karasawa","year":"2018","journal-title":"Contrib. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175440_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.174826","article-title":"Potential benefit of the cathepsin S inhibitor, ASP1617, as a treatment for systemic lupus erythematosus","volume":"919","author":"Kawato","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175440_bib27","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/rheumatology\/keaa053","article-title":"Immunological characteristics and possible pathogenic role of urinary CD11c+ macrophages in lupus nephritis","volume":"59","author":"Kim","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2022.175440_bib28","series-title":"Systemic Lupus Erythematosus","author":"Lahita","year":"2011"},{"key":"10.1016\/j.ejphar.2022.175440_bib29","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrrheum.2015.174","article-title":"Towards new avenues in the management of lupus glomerulonephritis","volume":"12","author":"Mok","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2022.175440_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1600-065X.1999.tb01361.x","article-title":"The role of lysosomal proteinases in MHC class II-mediated antigen processing and presentation","volume":"172","author":"Nakagawa","year":"1999","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2022.175440_bib31","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/art.20997","article-title":"Association of Epstein-Barr virus with systemic lupus erythematosus: effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype","volume":"52","author":"Parks","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2022.175440_bib32","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1681\/ASN.2004100820","article-title":"Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells","volume":"16","author":"Patole","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175440_bib33","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2006030263","article-title":"Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis","volume":"17","author":"Pawar","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175440_bib34","article-title":"Murine models of systemic lupus erythematosus","volume":"2011","author":"Perry","year":"2011","journal-title":"J. Biomed. Biotechnol."},{"key":"10.1016\/j.ejphar.2022.175440_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000270","article-title":"Interferon pathway in SLE: one key to unlocking the mystery of the disease","volume":"6","author":"Ronnblom","year":"2019","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ejphar.2022.175440_bib36","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2177\/jsci.38.135","article-title":"[The pathogenic role of macrophage in lupus nephritis]","volume":"38","author":"Sugiyama","year":"2015","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"10.1016\/j.ejphar.2022.175440_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.bcp.2017.10.001","article-title":"Cathepsin S inhibition suppresses autoimmune-triggered inflammatory responses in macrophages","volume":"146","author":"Thanei","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175440_bib38","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1073\/pnas.0914902107","article-title":"Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages","volume":"107","author":"Triantafyllopoulou","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2022.175440_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043317","article-title":"Toll-like receptor 7 stimulates the expression of Epstein-Barr virus latent membrane protein 1","volume":"7","author":"Valente","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2022.175440_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.ASN.0000108969.21691.5D","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"15","author":"Weening","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejphar.2022.175440_bib41","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/aps.2015.91","article-title":"Toll-like receptors: potential targets for lupus treatment","volume":"36","author":"Wu","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejphar.2022.175440_bib42","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/art.10441","article-title":"Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice","volume":"46","author":"Yoshida","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.ejphar.2022.175440_bib43","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.3892\/etm.2014.1578","article-title":"The expression of renal Epstein-Barr virus markers in patients with lupus nephritis","volume":"7","author":"Yu","year":"2014","journal-title":"Exp. Ther. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922007014?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299922007014?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:14:25Z","timestamp":1757978065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299922007014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":43,"alternative-id":["S0014299922007014"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175440","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a novel Poly (I:C)-induced murine model with accelerated lupus nephritis and examination of the therapeutic effects of mycophenolate mofetil and a cathepsin S inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175440","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"175440"}}